Improving Brain Tumor Segmentation at the Edge

 

Intel’s Abhishek Khowala, principal health AI engineer, and Séverine Habert, AI engineering manager, discuss some of the enhancements in brain tumor segmentation for enabling diagnosis.

While most brain tumors are benign, early detection is critical for the best treatment options and outcomes. Assessing a diagnosis starts with MRI 2D and 3D imaging. Segmentation of the brain tumor – or separating the tumor from normal brain tissues – is essential to identifying three key factors to allow doctors to move forward:

  1. Is the tumor benign or malignant?
  2. The approximate tumor size and location.
  3. Plan out the treatment options.

“We need to segment out the tumor from the rest of the tissues around it,” Khowala says. “For that, there is the unit model. And that architecture works with fewer amounts of data yet provides a clearer segmentation result.”

The brain tumor segmentation (BraTS) combined with OpenVINO™ toolkit could optimize MRI results during tumor detection and monitoring. “Since this is something that has to happen worldwide, we need to deploy it at scale,” Khowala explains. Scaling requires overcoming a few challenges. Utilizing OpenVINO erases issues of high-cost GPU required for deploying AI solutions or perceived performance limitations of common frameworks such as PyTorch or TensorFlow. “Brain tumor segmentation is a perfect example of applying the most common architecture and using it for multiple devices from edge to handheld devices,” Habert adds.

For optimized AI, the provided data must be robust, which is not an easy task. According to Khowala, Expert radiologists are required to interpret the MRI images to get to the ground truth data. BraTS helps predict results and compare accuracy with provided ground truth results using the Sørensen–Dice coefficient datasets. Once the data is available, modeling can take place and assist medical professionals in their diagnosis.

Learn more about brain tumor segmentation solutions by connecting with Abhishek Khowala and Séverine Habert on LinkedIn or visit:

https://www.intel.com/content/www/us/en/healthcare-it/healthcare-overview.html.

Subscribe to this channel on Apple Podcasts, Spotify, and Google Podcasts to hear more from the Intel Internet of Things Group.

Follow us on social media for the latest updates in B2B!

Image

Latest

AMAG Technology
AMAG Technology: Control, Reliability, and Customer-First Supply Chain Excellence
April 2, 2025

At AMAG Technology, being customer-obsessed goes beyond a mindset—it’s built into every part of the operation. One of the company’s greatest strengths lies in its ability to manufacture its own products, offering a level of supply chain control that few competitors can match. Allan Price, Head of Global Supply Chain at AMAG, emphasizes how this…

Read More
visitor management solution
Reinventing Visitor Management Solution with Symmetry GUEST
April 2, 2025

In an age where speed and security are paramount, the traditional paper logbook is becoming a relic of the past. AMAG Technology’s Symmetry Guest system offers a modern, digital solution that redefines the way organizations welcome and manage visitors. Gone are the days of long lines and confusion at the front desk—Symmetry Guest empowers hosts…

Read More
AMAG
Driven by Customers, Defined by Innovation: Inside AMAG’s Customer-Obsessed Approach
April 2, 2025

AMAG Technology continues to strengthen its customer-obsessed culture by actively listening to both internal and external voices. As shared by Kyle Gordon, Executive Vice President of Global Sales, Marketing, & Commercial Excellence, the company is focused on improving processes, responding with speed, and driving innovation—while honoring its legacy and delivering unique value within the industry.

Read More
biotech
Biotech Moves Smarter: IDDI Powers Data-Driven Drug Innovation
April 2, 2025

As biotech innovation accelerates, small and mid-size pharmaceutical companies are becoming key players in bringing new treatments to market. Yet many of these organizations face steep challenges when navigating clinical trial design, regulatory approval, and data integrity. According to a McKinsey Global Institute report, industries like biotech could help generate up to $50 trillion…

Read More